TITLE

New PAH drug improves exercise capacity

AUTHOR(S)
Belden, Heidi
PUB. DATE
July 2007
SOURCE
Drug Topics;7/23/2007, Vol. 151 Issue 14, p44
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the U.S. Food and Drug Administration's approval of once-daily oral tablet ambrisentan from Gilead Sciences Inc. for the treatment of pulmonary arterial hypertension with World Health Organization Functional Class II or III symptoms. The drug is an endothelin receptor antagonist selective for the endothelin type-A receptor. Its efficacy was proven in two 12-week phase III clinical trials. It was demonstrated to be teratogenic in rats and may cause fetal harm if given to a pregnant woman. The initial dose is 5 mg, with or without food, and can be increased to 10 mg if 5 mg is well tolerated, according to the prescribing information.
ACCESSION #
26131631

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics